The following represents disclosure information provided by authors of this abstract. The Genitourinary Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I study of high-dose interleukin (HD-IL2) and sorafenib in patients with metastatic clear cell renal cell carcinoma (RCC) and melanoma.
Elaine Tat Lam
No relevant relationships to disclose
Gregory Lesinski
No relevant relationships to disclose
Amir Mortazavi
No relevant relationships to disclose
Kari Lynn Kendra
No relevant relationships to disclose
William Edgar Carson
No relevant relationships to disclose
Sanaa Tahiri
No relevant relationships to disclose
Ryan Liersemann
No relevant relationships to disclose
Steven K. Clinton
No relevant relationships to disclose
Thomas Olencki
No relevant relationships to disclose
J. P. Monk
No relevant relationships to disclose